Folkert Asselbergs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3205910/publications.pdf

Version: 2024-02-01

561 papers

33,898 citations

77 h-index 159 g-index

601 all docs

601 docs citations

601 times ranked

49136 citing authors

#	Article	IF	Citations
1	Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. European Heart Journal, 2022, 43, 1104-1120.	1.0	37
2	Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Netherlands Heart Journal, 2022, 30, 84-95.	0.3	10
3	Sex disparity in subsequent outcomes in survivors of coronary heart disease. Heart, 2022, 108, 37-45.	1.2	9
4	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. American Journal of Cardiovascular Drugs, 2022, 22, 195-206.	1.0	13
5	Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers. European Heart Journal Cardiovascular Imaging, 2022, 23, 1492-1501.	0.5	6
6	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace, 2022, 24, 296-305.	0.7	9
7	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 761-769.	1.8	11
8	Disease management with home telemonitoring aimed at substitution of usual care in the Netherlands: Post-hoc analyses of the e-Vita HF study. Journal of Cardiology, 2022, 79, 1-5.	0.8	1
9	Missing data is poorly handled and reported in prediction model studies using machine learning: a literature review. Journal of Clinical Epidemiology, 2022, 142, 218-229.	2.4	60
10	Reply to the Letter to the Editor: "lt is urgent to evaluate the efficacy and safety of genotype guided antiplatelet therapy in patients after percutaneous coronary intervention in East Asian― International Journal of Cardiology, 2022, 348, 57.	0.8	0
11	Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010221.	2.1	5
12	A populationâ€based study of 92 clinically recognized risk factors for heart failure: coâ€occurrence, prognosis and preventive potential. European Journal of Heart Failure, 2022, 24, 466-480.	2.9	14
13	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
14	Prognostic value of strain by feature-tracking cardiac magnetic resonance in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2022, 24, 98-107.	0.5	15
15	Chromatin Immunoprecipitation Sequencing (ChIP-seq) Protocol for Small Amounts of Frozen Biobanked Cardiac. Methods in Molecular Biology, 2022, 2458, 97-111.	0.4	1
16	Nudging within learning health systems: next generation decision support to improve cardiovascular care. European Heart Journal, 2022, 43, 1296-1306.	1.0	16
17	The role of cognitive and brain reserve in memory decline and atrophy rate in mid and late-life: The SMART-MR study. Cortex, 2022, 148, 204-214.	1.1	9
18	Relation of Iron Status to Prognosis After Acute Coronary Syndrome. American Journal of Cardiology, 2022, 168, 22-30.	0.7	6

#	Article	IF	CITATIONS
19	The year in cardiovascular medicine 2021: digital health and innovation. European Heart Journal, 2022, 43, 271-279.	1.0	26
20	Dissecting the ILâ€6 pathway in cardiometabolic disease: A Mendelian randomization study on both <i>IL6</i> and <i>IL6R</i> . British Journal of Clinical Pharmacology, 2022, 88, 2875-2884.	1.1	29
21	Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia, 2022, 65, 644-656.	2.9	41
22	Modeling the His-Purkinje Effect in Non-invasive Estimation of Endocardial and Epicardial Ventricular Activation. Annals of Biomedical Engineering, 2022, 50, 343-359.	1.3	6
23	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers, 2022, 27, 264-269.	0.9	3
24	Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003553.	1.6	5
25	Echocardiographic Deformation ImagingÂfor Early Detection of GeneticÂCardiomyopathies. Journal of the American College of Cardiology, 2022, 79, 594-608.	1.2	10
26	Intersecting single-cell transcriptomics and genome-wide association studies identifies crucial cell populations and candidate genes for atherosclerosis. European Heart Journal Open, 2022, 2, oeab043.	0.9	34
27	Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. European Heart Journal Open, 2022, 2, .	0.9	13
28	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 306-318.	1.3	10
29	Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus. Nature Communications, 2022, 13, 1222.	5.8	5
30	Multiâ€phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. Journal of Thrombosis and Haemostasis, 2022, 20, 1331-1349.	1.9	12
31	Trends for Readmission and Mortality After Heart Failure Hospitalisation in Malaysia, 2007 to 2016. Global Heart, 2022, 17, 20.	0.9	6
32	Learning from individualised variation for evidence generation within a learning health system. British Journal of Anaesthesia, 2022, , .	1.5	1
33	The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis. Netherlands Heart Journal, 2022, 30, 190-197.	0.3	5
34	Multi-task Deep Learning of Myocardial Blood Flow and Cardiovascular Risk Traits from PET Myocardial Perfusion Imaging. Journal of Nuclear Cardiology, 2022, 29, 3300-3310.	1.4	3
35	Genetic variants associated with low-density lipoprotein cholesterol and systolic blood pressure and the risk of recurrent cardiovascular disease in patients with established vascular disease. Atherosclerosis, 2022, , .	0.4	1
36	Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. BMC Geriatrics, 2022, 22, 184.	1.1	35

3

#	Article	IF	CITATIONS
37	LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review. Current Heart Failure Reports, 2022, 19, 136-145.	1.3	6
38	Prognostic Significance of Ventricular Arrhythmias in 13Â444 Patients With Acute Coronary Syndrome: A Retrospective Cohort Study Based on Routine Clinical Data (NIHR Health Informatics Collaborative) Tj ETQq0 (0 1 ggBT /C	Ove z lock 10 T
39	Electrocardiogram-based mortality prediction in patients with COVID-19 using machine learning. Netherlands Heart Journal, 2022, 30, 312-318.	0.3	6
40	The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19. Hypertension Research, 2022, 45, 834-845.	1.5	18
41	Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Research, 2022, 60, 102737.	0.3	3
42	Prevalence of <i>CYP2C19*2</i> carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. Drug Metabolism and Personalized Therapy, 2022, 37, 35-40.	0.3	2
43	Life-threatening ventricular arrhythmia prediction in patients with dilated cardiomyopathy using explainable electrocardiogram-based deep neural networks. Europace, 2022, 24, 1645-1654.	0.7	10
44	Automatic Identification of Patients With Unexplained Left Ventricular Hypertrophy in Electronic Health Record Data to Improve Targeted Treatment and Family Screening. Frontiers in Cardiovascular Medicine, 2022, 9, 768847.	1.1	7
45	Unravelling the Difference Between Men and Women in Post-CABG Survival. Frontiers in Cardiovascular Medicine, 2022, 9, 768972.	1.1	2
46	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	1.0	35
47	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. PLoS Medicine, 2022, 19, e1003911.	3.9	21
48	Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease. European Heart Journal, 2022, 43, 2921-2930.	1.0	50
49	Implications of elevated troponin on time-to-surgery in non-ST elevation myocardial infarction (NIHR) Tj ETQq $1\ 1$	0.784314 0.8	f rgBT /Overlo
50	How Traditional Informed Consent Impairs Inclusivity in a Learning Healthcare System: Lessons Learned from the Utrecht Cardiovascular Cohort. Journal of Clinical Epidemiology, 2022, , .	2.4	4
51	Lifestyle changes and kidney function: A 10â€year followâ€up study in patients with manifest cardiovascular disease. European Journal of Clinical Investigation, 2022, 52, e13814.	1.7	2
52	Lowâ€Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific. Journal of the American Heart Association, 2022, 11, .	1.6	15
53	Genetic Basis of Dilated Cardiomyopathy in Dogs and Its Potential as a Bidirectional Model. Animals, 2022, 12, 1679.	1.0	5
54	Bloodâ€based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and metaâ€analysis. ESC Heart Failure, 2022, 9, 3418-3434.	1.4	6

#	Article	IF	CITATIONS
55	Interatrial Block Predicts Lifeâ€Threatening Arrhythmias in Dilated Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	1.6	4
56	Candidate Plasma Biomarkers to Detect Anthracyclineâ€Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study. Journal of the American Heart Association, 2022, 11, .	1.6	3
57	A head-to-head comparison of speckle tracking echocardiography and feature tracking cardiovascular magnetic resonance imaging in right ventricular deformation. European Heart Journal Cardiovascular Imaging, 2021, 22, 950-958.	0.5	13
58	The relation between VLDL-cholesterol and risk of cardiovascular events in patients with manifest cardiovascular disease. International Journal of Cardiology, 2021, 322, 251-257.	0.8	13
59	Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodelling. Cardiovascular Research, 2021, 117, 1532-1545.	1.8	37
60	Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. International Journal of Cardiology, 2021, 325, 140-148.	0.8	12
61	Text-mining in electronic healthcare records can be used as efficient tool for screening and data collection in cardiovascular trials: a multicenter validation study. Journal of Clinical Epidemiology, 2021, 132, 97-105.	2.4	23
62	ONCOR: design of the Dutch cardio-oncology registry. Netherlands Heart Journal, 2021, 29, 288-294.	0.3	3
63	Sex Differences in the Risk of Coronary Heart Disease Associated With Type 2 Diabetes: A Mendelian Randomization Analysis. Diabetes Care, 2021, 44, 556-562.	4.3	21
64	Early Mechanical Alterations in Phospholamban Mutation Carriers. JACC: Cardiovascular Imaging, 2021, 14, 885-896.	2.3	11
65	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & ESC Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	1.4	23
66	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
67	The association of the Mediterranean diet with heart failure risk in a Dutch population. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 60-66.	1.1	7
68	Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry. Netherlands Heart Journal, 2021, 29, 370-376.	0.3	7
69	The new <i>European Heart Journal </i> Digital Health and Innovations Team. European Heart Journal, 2021, 42, 1823-1824.	1.0	1
70	The year in cardiovascular medicine 2020: digital health and innovation. European Heart Journal, 2021, 42, 732-739.	1.0	20
71	Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007022.	1.6	58
72	Risk Factors and Prevalence of Dilated Cardiomyopathy in Sub-Saharan Africa: Protocol for a Systematic Review. JMIR Research Protocols, 2021, 10, e18229.	0.5	3

#	Article	IF	CITATIONS
73	Temporal Evolution of Serum Concentrations of Highâ€Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission. Journal of the American Heart Association, 2021, 10, e017393.	1.6	6
74	Risk stratification and subclinical phenotyping of dilated and/or arrhythmogenic cardiomyopathy mutation-positive relatives: CVON eDETECT consortium. Netherlands Heart Journal, 2021, 29, 301-308.	0.3	0
75	Sex, Age, and Socioeconomic Differences in Nonfatal Stroke Incidence and Subsequent Major Adverse Outcomes. Stroke, 2021, 52, 396-405.	1.0	28
76	Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients― International Journal of Infectious Diseases, 2021, 103, 560-561.	1.5	2
77	BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status. Netherlands Heart Journal, 2021, 29, 318-329.	0.3	7
78	COVID-19 related thrombi in ascending and descending thoracic aorta with peripheral embolization: a case report. European Heart Journal - Case Reports, 2021, 5, ytaa525.	0.3	6
79	Discovering and Visualizing Disease-Specific Electrocardiogram Features Using Deep Learning. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009056.	2.1	29
80	Diagnosis and Risk Prediction of Dilated Cardiomyopathy in the Era of Big Data and Genomics. Journal of Clinical Medicine, 2021, 10, 921.	1.0	16
81	Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open, 2021, 4, ooab001.	1.0	18
82	Propensity scoreâ€based analysis of longâ€term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support. ESC Heart Failure, 2021, 8, 1596-1603.	1.4	19
83	Automatic multilabel detection of ICD10 codes in Dutch cardiology discharge letters using neural networks. Npj Digital Medicine, 2021, 4, 37.	5.7	19
84	P62â€positive aggregates are homogenously distributed in the myocardium and associated with the type of mutation in genetic cardiomyopathy. Journal of Cellular and Molecular Medicine, 2021, 25, 3160-3166.	1.6	5
85	Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European Heart Journal, 2021, 42, 919-933.	1.0	113
86	Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study. BMJ Open, 2021, 11, e038881.	0.8	2
87	One year improvement of exercise capacity in patients with mechanical circulatory support as bridge to transplantation. ESC Heart Failure, 2021, 8, 1796-1805.	1.4	5
88	Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes. STAR Protocols, 2021, 2, 100334.	0.5	24
89	Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations. Clinical Epigenetics, 2021, 13, 61.	1.8	17
90	Temporal trends in heart failure medication prescription in a population-based cohort study. BMJ Open, 2021, 11, e043290.	0.8	7

#	Article	IF	Citations
91	Novel <i>CineECG</i> enables anatomical 3D localization and classification of bundle branch blocks. Europace, 2021, 23, i80-i87.	0.7	9
92	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. European Heart Journal, 2021, 42, 2000-2011.	1.0	49
93	End-stage kidney disease in patients with clinically manifest vascular disease; incidence and risk factors: results from the UCC-SMART cohort study. Journal of Nephrology, 2021, 34, 1511-1520.	0.9	2
94	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. Circulation: Cardiovascular Interventions, 2021, 14, e009434.	1.4	14
95	The year in cardiovascular medicine 2020: digital health and innovation. Russian Journal of Cardiology, 2021, 26, 4425.	0.4	2
96	Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans. Frontiers in Cardiovascular Medicine, 2021, 8, 658915.	1.1	3
97	Impact of cardiovascular disease and cardiovascular risk factors in hospitalised COVID-19 patients. Netherlands Heart Journal, 2021, 29, 13-19.	0.3	3
98	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	5.1	56
99	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology, 2021, , .	0.8	3
100	Persistent Symptoms and Health Needs of Women and Men With Non-Obstructed Coronary Arteries in the Years Following Coronary Angiography. Frontiers in Cardiovascular Medicine, 2021, 8, 670843.	1.1	5
101	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414
102	Right Ventricular FunctionalÂAbnormalities in Arrhythmogenic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 900-910.	2.3	26
103	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 973-982.	2.9	65
104	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction. European Heart Journal, 2021, 42, 2842-2850.	1.0	54
105	Real-time imputation of missing predictor values improved the application of prediction models in daily practice. Journal of Clinical Epidemiology, 2021, 134, 22-34.	2.4	22
106	Routine clinical care data from thirteen cardiac outpatient clinics: design of the Cardiology Centers of the Netherlands (CCN) database. BMC Cardiovascular Disorders, 2021, 21, 287.	0.7	7
107	Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease. International Journal of Cardiology, 2021, 334, 135-141.	0.8	6
108	Automatic Prediction of Recurrence of Major Cardiovascular Events: A Text Mining Study Using Chest X-Ray Reports. Journal of Healthcare Engineering, 2021, 2021, 1-11.	1.1	2

#	Article	IF	Citations
109	Heart failure medication dosage and survival in women and men seen at outpatient clinics. Heart, 2021, 107, 1748-1755.	1.2	20
110	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. International Journal of Cardiology, 2021, 334, 10-17.	0.8	4
111	Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup. Drug Metabolism and Personalized Therapy, 2021, .	0.3	1
112	Improving Diagnostic Value of Echocardiography in Arrhythmogenic Right Ventricular Cardiomyopathy Using Deformation Imaging. JACC: Cardiovascular Imaging, 2021, 14, 2481-2483.	2.3	3
113	Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. Circulation, 2021, 144, 382-392.	1.6	32
114	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	0.7	14
115	Internal-external cross-validation helped to evaluate the generalizability of prediction models in large clustered datasets. Journal of Clinical Epidemiology, 2021, 137, 83-91.	2.4	23
116	A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). International Journal of Cardiology, 2021, 339, 75-82.	0.8	9
117	The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541.	1.4	11
118	Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials. Journal of the American Heart Association, 2021, 10, e021115.	1.6	2
119	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
120	Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients. International Journal of Cardiology, 2021, 343, 15-20.	0.8	12
121	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
122	Real-time imputation of missing predictor values in clinical practice. European Heart Journal Digital Health, 2021, 2, 154-164.	0.7	8
123	Comparing Non-invasive Inverse Electrocardiography With Invasive Endocardial and Epicardial Electroanatomical Mapping During Sinus Rhythm. Frontiers in Physiology, 2021, 12, 730736.	1.3	7
124	A multivariate analysis identifies genetic loci associated with atherosclerotic plaque composition and cardiovascular disease trajectory. European Heart Journal, 2021, 42, .	1.0	0
125	Artificial intelligence in cardiology: the debate continues. European Heart Journal Digital Health, 2021, 2, 721-726.	0.7	6
126	Methodological issues in meta-analyses of real-world clinical data to infer causality. International Journal of Cardiology, 2021, 345, 107-108.	0.8	0

#	Article	IF	CITATIONS
127	An informatics consult approach for generating clinical evidence for treatment decisions. BMC Medical Informatics and Decision Making, 2021, 21, 281.	1.5	8
128	Massive expansion of human induced pluripotent stem cells resulting in efficient biobanking and functional 3D tissue analysis of genetic cardiomyopathies. European Heart Journal, 2021, 42, .	1.0	0
129	Risk, Clinical Course, and Outcome of Ischemic Stroke in Patients Hospitalized With COVID-19: A Multicenter Cohort Study. Stroke, 2021, 52, 3978-3986.	1.0	18
130	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. ESC Heart Failure, 2021, , .	1.4	4
131	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	13.7	353
132	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. Molecular Psychiatry, 2020, 25, 2392-2409.	4.1	83
133	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. European Journal of Preventive Cardiology, 2020, 27, 234-243.	0.8	10
134	Evolution of renal function and predictive value of serial renal assessments among patients with acute coronary syndrome: BIOMArCS study. International Journal of Cardiology, 2020, 299, 12-19.	0.8	3
135	Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls. Biological Psychiatry, 2020, 87, 409-418.	0.7	129
136	Association between betaâ€blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity scoreâ€matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 103-112.	2.9	27
137	Evaluation of Disease Progression in Arrhythmogenic Cardiomyopathy. JACC: Cardiovascular Imaging, 2020, 13, 631-634.	2.3	20
138	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 2020, 11, 163.	5.8	466
139	Adherence to the Dutch dietary guidelines and 15-year incidence of heart failure in the EPIC-NL cohort. European Journal of Nutrition, 2020, 59, 3405-3413.	1.8	5
140	Data mining information from electronic health records produced high yield and accuracy for current smoking status. Journal of Clinical Epidemiology, 2020, 118, 100-106.	2.4	25
141	Model selection for metabolomics: predicting diagnosis of coronary artery disease using automated machine learning. Bioinformatics, 2020, 36, 1772-1778.	1.8	42
142	AÂrandomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure. Netherlands Heart Journal, 2020, 28, 16-26.	0.3	24
143	Age at menarche and heart failure risk: The EPIC-NL study. Maturitas, 2020, 131, 34-39.	1.0	4
144	Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. Circulation Research, 2020, 127, 1437-1455.	2.0	283

#	Article	IF	Citations
145	Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy. Cardio-Oncology, 2020, 6, 23.	0.8	10
146	1041 Early detection of biventricular mechanical dysfunction in PLN R14del mutation carriers. European Heart Journal Cardiovascular Imaging, 2020, 21, .	0.5	0
147	P365 Echocardiographic deformation imaging improves detection of arrhythmogenic right ventricular cardiomyopathy; a head-to-head comparison of deformation imaging and conventional assessment. European Heart Journal Cardiovascular Imaging, 2020, 21, .	0.5	0
148	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
149	H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts. Clinical Epigenetics, 2020, 12, 106.	1.8	20
150	Functional investigation of the coronary artery disease gene SVEP1. Basic Research in Cardiology, 2020, 115, 67.	2.5	25
151	Cardiac complications in patients hospitalised with COVID-19. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 817-823.	0.4	108
152	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nature Genetics, 2020, 52, 1314-1332.	9.4	91
153	Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease. JACC: CardioOncology, 2020, 2, 400-410.	1.7	8
154	Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease. European Heart Journal, 2020, 41, 2618-2628.	1.0	61
155	Predicting major adverse cardiovascular events for secondary prevention: protocol for a systematic review and meta-analysis of risk prediction models. BMJ Open, 2020, 10, e034564.	0.8	16
156	Cardiovascular adverse events following treatment for non-Hodgkin lymphoma – Authors' reply. Lancet Haematology,the, 2020, 7, e557-e558.	2.2	0
157	Takotsubo cardiomyopathy in COVID-19: a case report. Haemodynamic and therapeutic considerations. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	19
158	Metabolic Age Based on the BBMRI-NL $\langle \sup 1 \langle \sup \rangle$ H-NMR Metabolomics Repository as Biomarker of Age-related Disease. Circulation Genomic and Precision Medicine, 2020, 13, 541-547.	1.6	50
159	Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. Lancet, The, 2020, 396, 623-634.	6.3	65
160	Strength of patient cohorts and biobanks for cardiomyopathy research. Netherlands Heart Journal, 2020, 28, 50-56.	0.3	1
161	Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, 387-395.	1.6	16
162	Prediction of vascular aging based on smartphone acquired PPG signals. Scientific Reports, 2020, 10, 19756.	1.6	37

#	Article	IF	Citations
163	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	0.8	30
164	Proteomic profiling of a large cohort of HCM patients: Genotype-specific protein changes. Journal of Molecular and Cellular Cardiology, 2020, 140, 7.	0.9	0
165	Family history and polygenic risk of cardiovascular disease: Independent factors associated with secondary cardiovascular events in patients undergoing carotid endarterectomy. Atherosclerosis, 2020, 307, 121-129.	0.4	13
166	Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. BMC Cardiovascular Disorders, 2020, 20, 268.	0.7	5
167	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
168	A registryâ€based algorithm to predict ejection fraction in patients with heart failure. ESC Heart Failure, 2020, 7, 2388-2397.	1.4	13
169	Natural Language Processing for Mimicking Clinical Trial Recruitment in Critical Care: AÂSemi-Automated Simulation Based on the LeoPARDS Trial. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 2950-2959.	3.9	28
170	Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants. Journal of Clinical Medicine, 2020, 9, 545.	1.0	12
171	Genome-wide association identifies seven loci for pelvic organ prolapse in Iceland and the UK Biobank. Communications Biology, 2020, 3, 129.	2.0	20
172	Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (The NIHR) Tj ETQq0 e013684.	0 0 rgBT /0 1.6	Overlock 10 Tr 16
173	Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematology,the, 2020, 7, e295-e308.	2.2	38
174	Assessing thyroid cancer risk using polygenic risk scores. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5997-6002.	3.3	39
175	Pulmonary artery pressureâ€guided therapy in ambulatory patients with symptomatic heart failure: the <scp>CardioMEMS E</scp> uropean <scp>M</scp> onitoring <scp>S</scp> tudy for <scp>H</scp> eart <scp>F</scp> ailure (<scp>MEMSâ€HF</scp>). European Journal of Heart Failure, 2020, 22, 1891-1901.	2.9	142
176	Genetic drug target validation using Mendelian randomisation. Nature Communications, 2020, 11, 3255.	5.8	175
177	ETM: Enrichment by topic modeling for automated clinical sentence classification to detect patients' disease history. Journal of Intelligent Information Systems, 2020, 55, 329-349.	2.8	10
178	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
179	Outcome of mechanical circulatory support at the University Medical Centre Utrecht. Netherlands Heart Journal, 2020, 28, 210-218.	0.3	5
180	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. Pharmacogenomics Journal, 2020, 20, 770-783.	0.9	22

#	Article	IF	Citations
181	High-frequency metabolite profiling and the incidence of recurrent cardiac events in patients with post-acute coronary syndrome. Biomarkers, 2020, 25, 235-240.	0.9	1
182	A mutation update for the <i>FLNC</i> gene in myopathies and cardiomyopathies. Human Mutation, 2020, 41, 1091-1111.	1.1	92
183	Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. Communications Biology, 2020, 3, 189.	2.0	30
184	CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. European Heart Journal, 2020, 41, 1795-1796.	1.0	41
185	Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. Human Molecular Genetics, 2020, 29, 1388-1395.	1.4	23
186	Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Failure, 2020, 7, 1224-1233.	1.4	20
187	The relation between healthy lifestyle changes and decrease in systemic inflammation in patients with stable cardiovascular disease. Atherosclerosis, 2020, 301, 37-43.	0.4	24
188	Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation. Europace, 2020, 22, 787-796.	0.7	40
189	Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart, 2020, 106, 1686-1692.	1.2	9
190	Predicting sustained ventricular arrhythmias in dilated cardiomyopathy: a metaâ€analysis and systematic review. ESC Heart Failure, 2020, 7, 1430-1441.	1.4	20
191	Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2099-2106.	1.4	13
192	Big Data and Artificial Intelligence: Opportunities and Threats in Electrophysiology. Arrhythmia and Electrophysiology Review, 2020, 9, 146-154.	1.3	22
193	Low-Density Lipoprotein Cholesterol Target Attainment in Patients With Established Cardiovascular Disease: Analysis of Routine Care Data. JMIR Medical Informatics, 2020, 8, e16400.	1.3	3
194	Automatic ICD-10 Classification of Diseases from Dutch Discharge Letters. , 2020, , .		10
195	Beyond GWAS in Atrial Fibrillation Genetics. Circulation Research, 2020, 126, 361-363.	2.0	0
196	Abstract P161: A Learning Healthcare System Improves Cardiovascular Risk Management: Results From the Utrecht Cardiovascular Cohort Initiative. Circulation, 2020, 141, .	1.6	0
197	Multimodal Learning for Cardiovascular Risk Prediction using EHR Data. , 2020, , .		8
198	Evaluating a cardiovascular disease risk management care continuum within a learning healthcare system: a prospective cohort study. BJGP Open, 2020, 4, bjgpopen20X101109.	0.9	4

#	Article	IF	Citations
199	Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients. Circulation, 2020, 142, .	1.6	O
200	92 aetiologic factors for heart failure: prevalence, co-occurrence, prognosis and potential for prevention in 170,885 incident HF cases. European Heart Journal, 2020, 41, .	1.0	0
201	Abstract 15527: Association Between Adrenergic Receptor Modulation and the Risk of Heart Failure: A Two-sample Mendelian Randomization Study. Circulation, 2020, 142, .	1.6	О
202	Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?. European Journal of Heart Failure, 2019, 21, 86-89.	2.9	0
203	The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort. European Journal of Medical Genetics, 2019, 62, 90-92.	0.7	26
204	Indoxyl Sulfate Stimulates Angiogenesis by Regulating Reactive Oxygen Species Production via CYP1B1. Toxins, 2019, 11, 454.	1.5	11
205	AÂcomputerised decision support system for cardiovascular risk management â€live' in the electronic health record environment: development, validation and implementationâ€"the Utrecht Cardiovascular Cohort Initiative. Netherlands Heart Journal, 2019, 27, 435-442.	0.3	19
206	CLINICAL IMPORTANCE OF TROPONIN LEVEL IN 3,121 PATIENTS PRESENTING WITH ATRIAL FIBRILLATION (AF-TROP STUDY). Journal of the American College of Cardiology, 2019, 73, 410.	1.2	0
207	Risk for HeartÂFailure. JACC: Heart Failure, 2019, 7, 637-647.	1.9	31
208	Cardiac amyloidosis: the need for early diagnosis. Netherlands Heart Journal, 2019, 27, 525-536.	0.3	73
209	Sequence variants with large effects on cardiac electrophysiology and disease. Nature Communications, 2019, 10, 4803.	5.8	28
210	337Value of feature tracking cardiovascular magnetic resonance imaging in detecting genotype-positive hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2019, 20, .	0.5	0
211	Use of Pharmacogenetic Drugs by the Dutch Population. Frontiers in Genetics, 2019, 10, 567.	1.1	32
212	Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovascular Disorders, 2019, 19, 240.	0.7	22
213	Family History And Polygenic Risk Of Cardiovascular Disease Are Associated With A Worse Secondary Cardiovascular Outcome In Patients Undergoing Carotid Endarterectomy. Atherosclerosis, 2019, 287, e87.	0.4	1
214	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	5.8	84
215	2153The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease; a cohort study. European Heart Journal, 2019, 40, .	1.0	2
216	Autosomal Sexual Dimorphism In Methylation Of Advanced Atherosclerotic Carotid Plaques. Atherosclerosis, 2019, 287, e66.	0.4	0

#	Article	IF	CITATIONS
217	Mapping Genes To Cardiovascular Susceptibility Loci At A Single-Cell Resolution. Atherosclerosis, 2019, 287, e21.	0.4	O
218	The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study. European Heart Journal, 2019, 40, 3901-3909.	1.0	54
219	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. New England Journal of Medicine, 2019, 381, 1621-1631.	13.9	431
220	Learning From Our Healthcare System: The Analysis Of Ldl-Cholesterol Target Attainment In Patients With Established Cardiovascular Disease In Routine Care Data. Atherosclerosis, 2019, 287, e84.	0.4	0
221	Genome-wide association meta-analysis of 30,000 samples identifies seven novel loci for quantitative ECG traits. European Journal of Human Genetics, 2019, 27, 952-962.	1.4	29
222	Targeted next-generation sequencing in Slovak cardiomyopathy patients. Bratislava Medical Journal, 2019, 120, 46-51.	0.4	2
223	Integrative Functional Annotation of 52 Genetic Loci Influencing Myocardial Mass Identifies Candidate Regulatory Variants and Target Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002328.	1.6	7
224	Enhancing cardiovascular artificial intelligence (AI) research in the Netherlands: CVON-AI consortium. Netherlands Heart Journal, 2019, 27, 414-425.	0.3	6
225	Discovery of biomarkers for the presence and progression of left ventricular diastolic dysfunction and HEart faiLure with Preserved ejection Fraction in patients at risk for cardiovascular disease: rationale and design of the HELPFul case-cohort study in a Dutch cardiology outpatient clinic. BMJ Open. 2019. 9. e028408.	0.8	8
226	UNRAVEL: big data analytics research data platform to improve care of patients with cardiomyopathies using routine electronic health records and standardised biobanking. Netherlands Heart Journal, 2019, 27, 426-434.	0.3	25
227	The Translational Landscape of the Human Heart. Cell, 2019, 178, 242-260.e29.	13.5	407
228	A comparison of two workflows for regulome and transcriptomeâ€based prioritization of genetic variants associated with myocardial mass. Genetic Epidemiology, 2019, 43, 717-726.	0.6	1
229	The effect of computerized decision support systems on cardiovascular risk factors: a systematic review and meta-analysis. BMC Medical Informatics and Decision Making, 2019, 19, 108.	1.5	36
230	Mortality Risk Associated With Truncating Founder Mutations in Titin. Circulation Genomic and Precision Medicine, 2019, 12, e002436.	1.6	5
231	Temporal Pattern of Growth Differentiation Factor- 15 Protein After Acute Coronary Syndrome (From) Tj ETQq $1\ 1$	0.784314 0.7	1 rgBT /Overlo
232	UNEXPECTED INVERTED U-SHAPED RELATIONSHIP BETWEEN TROPONIN LEVEL AND MORTALITY EXPLAINED BY REVASCULARIZATION IN BOTH PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROME (TROP-RISK) Tj E	TQuq2000	rg&T /Overloo
233	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
234	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22

#	Article	IF	Citations
235	The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update. Netherlands Heart Journal, 2019, 27, 480-486.	0.3	29
236	Increasing sensitivity—aÂcommon-sense approach?. Netherlands Heart Journal, 2019, 27, 287-288.	0.3	0
237	Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission. American Heart Journal, 2019, 216, 143-146.	1.2	3
238	Big data analytics in adult congenital heart disease: why coding matters. European Heart Journal, 2019, 40, 1078-1080.	1.0	3
239	Diagnostic Value of Native T1 Mapping inÂArrhythmogenic Right Ventricular Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 1580-1582.	2.3	17
240	Adverse Drug Reactions to Guideline-Recommended HeartÂFailureÂDrugs in Women. JACC: Heart Failure, 2019, 7, 258-266.	1.9	51
241	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 2019, 115, 1512-1518.	1.8	15
242	146â€The prognostic implication of a positive troponin across the age spectrum in a quarter of a million patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative Trop-risk) Tj ETQq0 0 C) rgBT /Ov	erl o ck 10 Tf 5
243	69â€The relationship between troponin level and mortality in an unselected population of over 250,000 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative Trop-risk) Tj ETQq1 1 C).784314 ı	rgBT Overloo
244	145â€The role of high-sensitivity C-reactive protein in predicting mortality beyond troponin in over 100,000 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative) Tj ETQq0 0 C	rgBT /Ove	erl o ck 10 Tf 5
245	30â€The prognostic implication of troponin level in over 3000 patients presenting with atrial fibrillation (NIHR Health Informatics Collaborative AF-trop Study). , 2019, , .		0
246	57â€Invasive versus medical management of elderly patients with non-ST elevation myocardial infarction (NIHR Health Informatics Collaborative Senior-NSTEMI study). , 2019, , .		0
247	P991Predicting arrhythmic risk in dilated cardiomyopathy: a systematic review & meta-analysis of clinical parameters. European Heart Journal, 2019, 40, .	1.0	1
248	P1540Major adverse limb events (MALE) and the relation with classical risk factors in patients with symptomatic cardiovascular disease. European Heart Journal, 2019, 40, .	1.0	0
249	Association of troponin level and age with mortality in 250 000 patients: cohort study across five UK acute care centres. BMJ, The, 2019, 367, I6055.	3.0	45
250	4943Remnant cholesterol increases the risk for recurrent vascular events independent of LDL-cholesterol in patients with clinical manifest vascular disease. European Heart Journal, 2019, 40, .	1.0	0
251	IFT10. Family History and Polygenic Risk of Cardiovascular Disease: Independent Factors Associated to Secondary Cardiovascular Outcome in Patients Undergoing Carotid Endarterectomy. Journal of Vascular Surgery, 2019, 69, e80.	0.6	0
252	Single Cell Rna-Sequencing Identifies Numerous Cell Sub-Types And Suggests Lineage Plasticity In Human Atherosclerotic Plaques. Atherosclerosis, 2019, 287, e96-e97.	0.4	0

#	Article	IF	CITATIONS
253	Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS. Data in Brief, 2019, 27, 104750.	0.5	10
254	Non-HLA Genetic Factors and Their Influence on Heart Transplant Outcomes: A Systematic Review. Transplantation Direct, 2019, 5, e422.	0.8	3
255	Cancer Therapy-Related CardiacÂDysfunction of NonanthracyclineÂChemotherapeutics. JACC: CardioOncology, 2019, 1, 280-290.	1.7	12
256	High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome. Circulation, 2019, 139, 134-136.	1.6	26
257	Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. Neurology, 2019, 92, .	1.5	30
258	Risk factors for incident heart failure in age―and sexâ€specific strata: a populationâ€based cohort using linked electronic health records. European Journal of Heart Failure, 2019, 21, 1197-1206.	2.9	49
259	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and AlcoholÂUse. Biological Psychiatry, 2019, 85, 946-955.	0.7	69
260	The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients. Biomarkers, 2019, 24, 199-205.	0.9	5
261	Sequence variants associating with urinary biomarkers. Human Molecular Genetics, 2019, 28, 1199-1211.	1.4	28
262	The Prognostic Value of RightÂVentricularÂDeformation Imaging inÂEarlyÂArrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 446-455.	2.3	64
263	Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets. Scientific Reports, 2018, 8, 3434.	1.6	43
264	Systems analysis of dilated cardiomyopathy in the next generation sequencing era. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2018, 10, e1419.	6.6	12
265	An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors. BMJ Open, 2018, 8, e018331.	0.8	31
266	Real-world management of heart failure in the Netherlands. Netherlands Heart Journal, 2018, 26, 240-241.	0.3	0
267	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. European Heart Journal, 2018, 39, 1481-1495.	1.0	163
268	Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm, 2018, 15, 1097-1107.	0.3	79
269	Genetics, Clinical Features, and Long-TermÂOutcome of NoncompactionÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 711-722.	1.2	242
270	Chemotherapy-Related Cardiac Dysfunction. Circulation Genomic and Precision Medicine, 2018, 11, e001753.	1.6	64

#	Article	lF	CITATIONS
271	Women-specific risk factors for heart failure: A genetic approach. Maturitas, 2018, 109, 104-111.	1.0	10
272	Feasibility and implementation of <i>CYP2C19</i> genotyping in patients using antiplatelet therapy. Pharmacogenomics, 2018, 19, 621-628.	0.6	19
273	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	1.0	94
274	The first titin (c.59926 \pm 1G > A) founder mutation associated with dilated cardiomyopathy. European Journal of Heart Failure, 2018, 20, 803-806.	2.9	16
275	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. European Journal of Heart Failure, 2018, 20, 89-96.	2.9	48
276	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm. JAMA Cardiology, 2018, 3, 26.	3.0	75
277	P2724Washout and long-term stabilization of cholesterols after acute coronary syndrome. European Heart Journal, 2018, 39, .	1.0	0
278	Genome-Wide Association Meta-Analysis for Acute Rejection of Kidney Transplants. Transplantation, 2018, 102, S27.	0.5	1
279	P71Targeted resequencing of coding and cardiac non-coding regulatory regions related to genes implicated in cardiomyopathy. Cardiovascular Research, 2018, 114, S19-S19.	1.8	0
280	P1558The time course of immuno- and inflammo-proteomics prior to a recurrent coronary event in post-acute coronary syndrome patients. European Heart Journal, 2018, 39, .	1.0	0
281	The Role of Loss-of-Function Mutations on Development of Rejection After Heart Transplantation. Journal of Heart and Lung Transplantation, 2018, 37, S324-S325.	0.3	0
282	Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nature Communications, 2018, 9, 4568.	5.8	44
283	A comprehensive evaluation of the genetic architecture of sudden cardiac arrest. European Heart Journal, 2018, 39, 3961-3969.	1.0	59
284	Dilated Cardiomyopathy DueÂtoÂBLC2-Associated AthanogeneÂ3Â(BAG3)ÂMutations. Journal of the American College of Cardiology, 2018, 72, 2471-2481.	1.2	93
285	Genetic Susceptibility Loci for Cardiovascular Disease and Their Impact on Atherosclerotic Plaques. Circulation Genomic and Precision Medicine, 2018, 11, e002115.	1.6	20
286	P6245High frequency metabolite profiling and the incidence of recurrent coronary events in post-acute coronary syndrome patients. European Heart Journal, 2018, 39, .	1.0	0
287	ExomeChip-Wide Analysis of 95 626 Individuals Identifies 10 Novel Loci Associated With QT and JT Intervals. Circulation Genomic and Precision Medicine, 2018, 11, e001758.	1.6	27
288	Smoking is Associated to DNA Methylation in Atherosclerotic Carotid Lesions. Circulation Genomic and Precision Medicine, 2018, 11, e002030.	1.6	23

#	Article	IF	Citations
289	Druggability of Coronary Artery Disease Risk Loci. Circulation Genomic and Precision Medicine, 2018, 11, e001977.	1.6	18
290	Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. Nature Communications, 2018, 9, 3636.	5.8	74
291	Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential. Cardiovascular Research, 2018, 114, 1828-1842.	1.8	40
292	P578Integrative functional annotation of 52 genetic loci influencing myocardial mass. Cardiovascular Research, 2018, 114, S141-S141.	1.8	0
293	Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease. PLoS ONE, 2018, 13, e0202682.	1.1	10
294	Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2018, 123, 59-63.	0.9	21
295	From lipid locus to drug target through human genomics. Cardiovascular Research, 2018, 114, 1258-1270.	1.8	17
296	Common and Rare Coding Genetic Variation Underlying the Electrocardiographic PR Interval. Circulation Genomic and Precision Medicine, 2018, 11, e002037.	1.6	19
297	Mendelian randomization: A powerful method to determine causality of biomarkers in diseases. International Journal of Cardiology, 2018, 268, 227-228.	0.8	2
298	Algorithms used in telemonitoring programmes for patients with chronic heart failure: A systematic review. European Journal of Cardiovascular Nursing, 2018, 17, 580-588.	0.4	22
299	Prescription patterns of angiotensinâ€converting enzyme inhibitors for various indications: A UK populationâ€based study. British Journal of Clinical Pharmacology, 2018, 84, 2365-2372.	1.1	24
300	PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nature Communications, 2018, 9, 2904.	5.8	71
301	Integrative Bioinformatics Approaches for Identification of Drug Targets in Hypertension. Frontiers in Cardiovascular Medicine, 2018, 5, 25.	1.1	3
302	Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Communications Biology, 2018, 1, 68.	2.0	42
303	Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6. Genome Biology, 2018, 19, 87.	3.8	47
304	Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: Data from the PREVEND study. International Journal of Cardiology, 2018, 272, 208-210.	0.8	8
305	Cardio-oncology: an overview on outpatient management and future developments. Netherlands Heart Journal, 2018, 26, 521-532.	0.3	31
306	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	9.4	286

#	Article	IF	Citations
307	Hematological Parameters Outperform Plasma Markers in Predicting Long-Term Mortality After Coronary Angiography. Angiology, 2018, 69, 600-608.	0.8	9
308	Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	16
309	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. Journal of Thrombosis and Haemostasis, 2017, 15, 465-472.	1.9	8
310	Rare and low-frequency coding variants alter human adult height. Nature, 2017, 542, 186-190.	13.7	544
311	Next-generation sequencing of a large gene panel in patients initially diagnosed with idiopathic ventricular fibrillation. Heart Rhythm, 2017, 14, 1035-1040.	0.3	31
312	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836.	1.2	214
313	Discovery of novel heart rate-associated loci using the Exome Chip. Human Molecular Genetics, 2017, 26, 2346-2363.	1.4	29
314	Genotypeâ€specific pathogenic effects in human dilated cardiomyopathy. Journal of Physiology, 2017, 595, 4677-4693.	1.3	42
315	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes and Endocrinology,the, 2017, 5, 97-105.	5.5	298
316	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	5.8	95
317	Uniform data collection in routine clinical practice in cardiovascular patients for optimal care, quality control and research: The Utrecht Cardiovascular Cohort. European Journal of Preventive Cardiology, 2017, 24, 840-847.	0.8	18
318	Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. Pharmacogenetics and Genomics, 2017, 27, 112-119.	0.7	16
319	Thirty years of heart transplantation at the University Medical Centre Utrecht. Netherlands Heart Journal, 2017, 25, 516-523.	0.3	13
320	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
321	Long-term cardiovascular health in adult cancer survivors. Maturitas, 2017, 105, 37-45.	1.0	14
322	Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. Journal of the American Heart Association, 2017, 6, .	1.6	89
323	Genetic variation within the Y chromosome is not associated with histological characteristics of the atherosclerotic carotid artery or aneurysmal wall. Atherosclerosis, 2017, 259, 114-119.	0.4	6
324	Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm, 2017, 14, 1024-1032.	0.3	59

#	Article	IF	Citations
325	Cardiorenal disease connection during post-menopause: The protective role of estrogen in uremic toxins induced microvascular dysfunction. International Journal of Cardiology, 2017, 238, 22-30.	0.8	16
326	Truncating Titin (TTN) Variants in Chemotherapy-Induced Cardiomyopathy. Journal of Cardiac Failure, 2017, 23, 476-479.	0.7	61
327	Additional Candidate Genes for Human Atherosclerotic Disease Identified Through Annotation Based on Chromatin Organization. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
328	Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a populationâ€based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure, 2017, 19, 1119-1127.	2.9	101
329	Life-long tailoring of management for patients with hypertrophic cardiomyopathy. Netherlands Heart Journal, 2017, 25, 186-199.	0.3	24
330	Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease. American Journal of Pathology, 2017, 187, 2645-2658.	1.9	35
331	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
332	New Blood Pressure–Associated Loci Identified in Meta-Analyses of 475 000 Individuals. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	48
333	A Comparison of Heritability Estimates by Classical Twin Modeling and Based on Genome-Wide Genetic Relatedness for Cardiac Conduction Traits. Twin Research and Human Genetics, 2017, 20, 489-498.	0.3	14
334	A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Scientific Reports, 2017, 7, 10252.	1.6	16
335	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovascular Pathology, 2017, 30, 23-26.	0.7	17
336	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. Pharmacogenomics, 2017, 18, 1143-1153.	0.6	5
337	Loss of Y Chromosome in Blood Is Associated With Major Cardiovascular Events During Follow-Up in Men After Carotid Endarterectomy. Circulation: Cardiovascular Genetics, 2017, 10, e001544.	5.1	78
338	Statin Effects on Metabolic Profiles. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
339	Monocyte gene expression in childhood obesity is associated with obesity and complexity of atherosclerosis in adults. Scientific Reports, 2017, 7, 16826.	1.6	16
340	Prognostic Value of Serial Galectinâ€3 Measurements in Patients With Acute Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	24
341	Reproductive factors in relation to heart failure in women: A systematic review. Maturitas, 2017, 106, 57-72.	1.0	13
342	A systematic comparison of cardiovascular magnetic resonance and high resolution histological fibrosis quantification in a chronic porcine infarct model. International Journal of Cardiovascular Imaging, 2017, 33, 1797-1807.	0.7	10

#	Article	IF	CITATIONS
343	Gene Set Enrichment Analyses: lessons learned from the heart failure phenotype. BioData Mining, 2017, 10, 18.	2.2	4
344	Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. American Journal of Cardiology, 2017, 120, 911-916.	0.7	32
345	Identifying gene–gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts. Human Genetics, 2017, 136, 165-178.	1.8	11
346	Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. Open Heart, 2017, 4, e000551.	0.9	26
347	Big Data in Cardiovascular Disease. European Heart Journal, 2017, 38, 1863-1865.	1.0	22
348	Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individuals. BioData Mining, 2017, 10, 25.	2.2	7
349	Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population. Global Heart, 2017, 12, 133.	0.9	4
350	Extending the use of GWAS data by combining data from different genetic platforms. PLoS ONE, 2017, 12, e0172082.	1.1	5
351	Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk. PLoS ONE, 2017, 12, e0182999.	1.1	5
352	Intronic Polymorphisms in the CDKN2B-AS1 Gene Are Strongly Associated with the Risk of Myocardial Infarction and Coronary Artery Disease in the Saudi Population. International Journal of Molecular Sciences, 2016, 17, 395.	1.8	32
353	Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. Nature Genetics, 2016, 48, 867-876.	9.4	41
354	Systematic analysis of chromatin interactions at disease associated loci links novel candidate genes to inflammatory bowel disease. Genome Biology, 2016, 17, 247.	3.8	39
355	The tip of the iceberg: challenges of accessing hospital electronic health record data for biological data mining. BioData Mining, 2016, 9, 29.	2.2	6
356	Early HTA in Pharmacogenomics: A Case Example in Cardiovascular Drugs. Value in Health, 2016, 19, A636.	0.1	1
357	Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndromeâ€"a prospective multicentre biomarker study conducted in the Netherlands. BMJ Open, 2016, 6, e012929.	0.8	18
358	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics, 2016, 17, 583-591.	0.6	9
359	Coding Variation in <i>ANGPTL4,LPL,</i> and <i>SVEP1</i> and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	13.9	427
360	Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1240-1246.	1.1	44

#	Article	IF	Citations
361	Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Human Genetics, 2016, 135, 453-467.	1.8	15
362	Cystatin C and Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 68, 934-945.	1.2	109
363	Pleiotropic molecular targets of coxibs reveals novel genomic loci conferring coronary artery disease risk. Atherosclerosis, 2016, 252, e252-e253.	0.4	1
364	Genetic analysis of emerging risk factors in coronary artery disease. Atherosclerosis, 2016, 254, 35-41.	0.4	11
365	Plasminogen Activator Inhibitor†and Diagnosis of the Metabolic Syndrome in a West African Population. Journal of the American Heart Association, 2016, 5, .	1.6	21
366	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology, 2016, 1, 692.	3.0	233
367	Determinants of angiotensinâ€converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. British Journal of Clinical Pharmacology, 2016, 82, 1647-1659.	1.1	31
368	Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease. International Journal of Angiology, 2016, 25, 210-218.	0.2	1
369	52 Genetic Loci Influencing MyocardialÂMass. Journal of the American College of Cardiology, 2016, 68, 1435-1448.	1.2	113
370	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nature Genetics, 2016, 48, 1151-1161.	9.4	261
371	Characteristic adaptations of the extracellular matrix in dilated cardiomyopathy. International Journal of Cardiology, 2016, 220, 634-646.	0.8	50
372	Exome Array Analysis of Susceptibility to Pneumococcal Meningitis. Scientific Reports, 2016, 6, 29351.	1.6	7
373	High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. European Journal of Vascular and Endovascular Surgery, 2016, 52, 198-204.	0.8	24
374	Associations of Comorbidities and Co-Medications with Angioedema during the Use of Angiotensin Converting Enzyme-Inhibitors within the United Kingdom Clinical Practice Research Datalink. Value in Health, 2016, 19, A39.	0.1	0
375	The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients. Journal of Heart and Lung Transplantation, 2016, 35, S191.	0.3	0
376	Health-related quality of life and outcome in atherosclerosis â€" Does sex matter?. International Journal of Cardiology, 2016, 212, 303-306.	0.8	3
377	Women Undergoing Coronary Angiography for Myocardial Infarction or Who Present With Multivessel Disease Have a Poorer Prognosis Than Men. Angiology, 2016, 67, 571-581.	0.8	4
378	Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. International Journal of Epidemiology, 2016, 45, 1927-1937.	0.9	94

#	Article	IF	Citations
379	Routinely analyzed leukocyte characteristics improve prediction of mortality after coronary angiography. European Journal of Preventive Cardiology, 2016, 23, 1211-1220.	0.8	22
380	The ethnicity-specific association of biomarkers with the angiographic severity of coronary artery disease. Netherlands Heart Journal, 2016, 24, 188-198.	0.3	10
381	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	1.0	56
382	Genome-wide association studies identify genetic loci for low von Willebrand factor levels. European Journal of Human Genetics, 2016, 24, 1035-1040.	1.4	45
383	Exome-Wide Association Analysis of Coronary Artery Disease in the Kingdom of Saudi Arabia Population. PLoS ONE, 2016, 11, e0146502.	1.1	7
384	Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PLoS ONE, 2016, 11, e0162753.	1.1	41
385	Extensive Association of Common Disease Variants with Regulatory Sequence. PLoS ONE, 2016, 11, e0165893.	1.1	7
386	Investigation of KIF6Trp719Arg gene polymorphism in a case-control study of coronary artery disease and non-fatal myocardial infarction in the Eastern Province of Saudi Arabia. Annals of Saudi Medicine, 2016, 36, 105-111.	0.5	3
387	Gender differences in health-related quality of life in patients undergoing coronary angiography. Open Heart, 2015, 2, e000231.	0.9	46
388	Identifying gene-gene interactions that are highly associated with Body Mass Index using Quantitative Multifactor Dimensionality Reduction (QMDR). BioData Mining, 2015, 8, 41.	2.2	17
389	Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Medicine, 2015, 7, 90.	3.6	49
390	Design and Implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation, 2015, 99, 2401-2412.	0.5	60
391	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378.	1.5	331
392	Inter-Ethnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. PLoS ONE, 2015, 10, e0131977.	1.1	13
393	Ethnicity Modifies Associations between Cardiovascular Risk Factors and Disease Severity in Parallel Dutch and Singapore Coronary Cohorts. PLoS ONE, 2015, 10, e0132278.	1.1	28
394	Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular Events. PLoS ONE, 2015, 10, e0132321.	1.1	141
395	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nature Communications, 2015, 6, 6955.	5.8	155
396	Sex matters to the heart: A special issue dedicated to the impact of sex related differences of cardiovascular diseases. Atherosclerosis, 2015, 241, 205-207.	0.4	32

#	Article	IF	Citations
397	Severity of stable coronary artery disease and its biomarkers differ between men and women undergoing angiography. Atherosclerosis, 2015, 241, 234-240.	0.4	20
398	A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscleâ€specific genes. European Journal of Heart Failure, 2015, 17, 484-493.	2.9	58
399	A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. Diabetes, 2015, 64, 3028-3036.	0.3	98
400	Hematological Parameters Improve Prediction of Mortality and Secondary Adverse Events in Coronary Angiography Patients. Medicine (United States), 2015, 94, e1992.	0.4	25
401	Variants in ALOX5, ALOX5AP and LTA4H are not associated with atherosclerotic plaque phenotypes: The Athero-Express Genomics Study. Atherosclerosis, 2015, 239, 528-538.	0.4	22
402	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	13.7	3,823
403	Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease. Atherosclerosis, 2015, 239, 451-458.	0.4	31
404	Genotype-guided coumarin dosing: where are we now and where do we need to go next?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 509-522.	1.5	4
405	Common variants associated with blood lipid levels do not affect carotid plaque composition. Atherosclerosis, 2015, 242, 351-356.	0.4	6
406	Prevalence and risk of cardiovascular risk factors and events in offspring of patients at high vascular risk and effect of location of parental vascular disease. International Journal of Cardiology, 2015, 195, 195-202.	0.8	6
407	Directional dominance on stature and cognition inÂdiverse human populations. Nature, 2015, 523, 459-462.	13.7	173
408	The Amount of Autophagy-Related Cardiomyocyte Cell Death Is Associated With the Type of Pathogenic Mutation in Genetic Dilated Cardiomyopathy. Journal of Heart and Lung Transplantation, 2015, 34, S38-S39.	0.3	0
409	Long-term outcome in men and women after CABG; results from theÂlMAGINE trial. Atherosclerosis, 2015, 241, 284-288.	0.4	35
410	Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal, 2015, 36, 539-550.	1.0	567
411	The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk. American Heart Journal, 2015, 170, 744-752.e2.	1.2	4
412	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 2015, 47, 1282-1293.	9.4	294
413	Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. International Journal of Clinical Pharmacy, 2015, 37, 1095-1103.	1.0	16
414	Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency. Genetics in Medicine, 2015, 17, 989-994.	1.1	48

#	Article	IF	CITATIONS
415	An Independent Filter for Gene Set Testing Based on Spectral Enrichment. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2015, 12, 1076-1086.	1.9	6
416	Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy. Netherlands Heart Journal, 2015, 23, 356-362.	0.3	6
417	Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. International Journal of Cardiology, 2015, 201, 644-645.	0.8	6
418	Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease. Atherosclerosis, 2015, 242, 605-610.	0.4	9
419	Genetic meta-analysis of 15,901 African Americans identifies variation in EXOC3L1 is associated with HDL concentration. Journal of Lipid Research, 2015, 56, 1781-1786.	2.0	11
420	Angiotensin Converting Enzyme Inhibitors Prescribing Pattern For Different Indications: A Population Based Study. Value in Health, 2015, 18, A402.	0.1	0
421	Impact of carotid atherosclerosis loci on cardiovascular events. Atherosclerosis, 2015, 243, 466-468.	0.4	18
422	Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet, The, 2015, 385, 867-874.	6.3	47
423	Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. International Journal of Obesity, 2015, 39, 265-269.	1.6	21
424	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	6.3	562
425	Biomarkers of Coronary Artery Disease Differ Between Asians and Caucasians in the General Population. Global Heart, 2015, 10, 301.	0.9	28
426	Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population. PLoS ONE, 2015, 10, e0136379.	1.1	8
427	The GENIUS-CHD consortium. European Heart Journal, 2015, 36, 2674-6.	1.0	14
428	Rs964184 (APOA5-A4-C3-A1) Is Related to Elevated Plasma Triglyceride Levels, but Not to an Increased Risk for Vascular Events in Patients with Clinically Manifest Vascular Disease. PLoS ONE, 2014, 9, e101082.	1.1	22
429	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial <i>STXBP5</i> and <i>STX2</i> . Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1093-1101.	1.1	43
430	Dissecting the obesity disease landscape: Identifying gene-gene interactions that are highly associated with body mass index. , 2014, , .		1
431	Plateletâ€reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2014, 12, 736-747.	1.9	83
432	<scp>LDL</scp> â€câ€linked <scp>SNP</scp> s are associated with <scp>LDL</scp> â€c and myocardial infarction despite lipidâ€lowering therapy in patients with established vascular disease. European Journal of Clinical Investigation, 2014, 44, 184-191.	1.7	13

#	Article	IF	CITATIONS
433	Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci. American Journal of Human Genetics, 2014, 94, 349-360.	2.6	158
434	Elevated urinary albumin excretion complements the Framingham Risk Score for the prediction of cardiovascular risk — response to treatment in the PREVEND IT trial. International Journal of Cardiology Heart & Vessels, 2014, 4, 193-197.	0.5	0
435	Genetic Variants at Chromosome 9p21 and RiskÂof First Versus Subsequent Coronary HeartÂDisease Events. Journal of the American College of Cardiology, 2014, 63, 2234-2245.	1.2	44
436	CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal, 2014, 168, 16-22.e1.	1,2	71
437	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. Clinical Pharmacology and Therapeutics, 2014, 95, 314-320.	2.3	12
438	The ENCODE Project and Perspectives on Pathways. Genetic Epidemiology, 2014, 38, 275-280.	0.6	47
439	A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease. Atherosclerosis, 2014, 237, 5-12.	0.4	27
440	Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA) Tj ETQqO 0 0 rgBT 144-150.	Overlock : 5.1	10 Tf 50 467 22
441	Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics. Nature Methods, 2014, 11, 868-874.	9.0	70
442	Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet, The, 2014, 384, 591-598.	6.3	510
443	Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186.	9.4	1,818
444	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ, The, 2014, 349, g4164-g4164.	3.0	528
445	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	9.4	281
446	Causal Effects of Body Mass Index on Cardiometabolic Traits and Events: A Mendelian Randomization Analysis. American Journal of Human Genetics, 2014, 94, 312.	2.6	0
447	Causal Effects of Body Mass Index on Cardiometabolic Traits and Events: A Mendelian Randomization Analysis. American Journal of Human Genetics, 2014, 94, 198-208.	2.6	199
448	Human validation of genes associated with a murine atherosclerotic phenotype. Atherosclerosis, 2014, 237, e3.	0.4	0
449	High Resolution Systematic Digital Histological Quantification of Cardiac Fibrosis and Adipose Tissue in Phospholamban p.Arg14del Mutation Associated Cardiomyopathy. PLoS ONE, 2014, 9, e94820.	1.1	30
450	The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?. Current Molecular Medicine, 2014, 14, 841-848.	0.6	5

#	Article	IF	Citations
451	SESSION INTRODUCTION: CHARACTERIZING THE IMPORTANCE OF ENVIRONMENTAL EXPOSURES, INTERACTIONS BETWEEN THE ENVIRONMENT AND GENETIC ARCHITECTURE, AND GENETIC INTERACTIONS: NEW METHODS FOR UNDERSTANDING THE ETIOLOGY OF COMPLEX TRAITS AND DISEASE. , 2014, , .		0
452	Cell Therapy, a Novel Remedy for Dilated Cardiomyopathy? A Systematic Review. Journal of Cardiac Failure, 2013, 19, 494-502.	0.7	25
453	Meta-analysis of Gene-Level Associations for Rare Variants Based on Single-Variant Statistics. American Journal of Human Genetics, 2013, 93, 236-248.	2.6	60
454	A gene-centric study of common carotid artery remodelling. Atherosclerosis, 2013, 226, 440-446.	0.4	9
455	The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. European Heart Journal, 2013, 34, 2896-2904.	1.0	32
456	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	1.2	115
457	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 1663-1678.	1.4	141
458	ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study). Netherlands Heart Journal, 2013, 21, 567-571.	0.3	15
459	Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. European Journal of Heart Failure, 2013, 15, 628-636.	2.9	148
460	Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics, 2013, 14, 249-260.	0.6	52
461	Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nature Genetics, 2013, 45, 501-512.	9.4	578
462	Interleukin-6 receptor pathways in abdominal aortic aneurysm. European Heart Journal, 2013, 34, 3707-3716.	1.0	143
463	Human Genetic Evidence that Common Variants near PIK3CG are Associated with Atherosclerotic Plaque Hemorrhage and Vessel Density. European Heart Journal, 2013, 34, 770-770.	1.0	1
464	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 3394-3395.	1.4	1
465	Genome-Wide Association Study on Plasma Levels of Midregional-Proadrenomedullin and C-Terminal-Pro-Endothelin-1. Hypertension, 2013, 61, 602-608.	1.3	34
466	Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. Human Molecular Genetics, 2013, 22, 184-201.	1.4	82
467	Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenetics and Genomics, 2013, 23, 518-525.	0.7	23
468	Progress in genetic association studies of plasma lipids. Current Opinion in Lipidology, 2013, 24, 123-128.	1.2	11

#	Article	IF	CITATIONS
469	A Simple and Computationally Efficient Approach to Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits. PLoS ONE, 2013, 8, e66545.	1.1	82
470	A concise history of genome-wide association studies. Saudi Journal of Medicine and Medical Sciences, 2013, 1, 4.	0.3	1
471	Omecamtiv mecarbil: a promising new drug in systolic heart failure. European Journal of Heart Failure, 2012, 14, 232-233.	2.9	14
472	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, The, 2012, 379, 1205-1213.	6.3	668
473	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, The, 2012, 379, 1214-1224.	6.3	886
474	Genetic determinants of the ankle-brachial index: A meta-analysis of a cardiovascular candidate gene 50K SNP panel in the candidate gene association resource (CARe) consortium. Atherosclerosis, 2012, 222, 138-147.	0.4	25
475	Genetics of coronary artery disease: Genome-wide association studies and beyond. Atherosclerosis, 2012, 225, 1-10.	0.4	59
476	Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood, 2012, 120, 4873-4881.	0.6	90
477	Seventy-five genetic loci influencing the human red blood cell. Nature, 2012, 492, 369-375.	13.7	320
478	Association Between Chromosome 9p21 Variants and the Ankle-Brachial Index Identified by a Meta-Analysis of 21 Genome-Wide Association Studies. Circulation: Cardiovascular Genetics, 2012, 5, 100-112.	5.1	98
479	Simultaneous pulmonary, cerebral and coronary emboli. International Journal of Cardiology, 2012, 157, e18-e20.	0.8	1
480	Gene ontology analysis of pairwise genetic associations in two genome-wide studies of sporadic ALS. BioData Mining, 2012, 5, 9.	2.2	11
481	FTO genotype is associated with phenotypic variability of body mass index. Nature, 2012, 490, 267-272.	13.7	383
482	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
483	Dominant missense mutations in ABCC9 cause Cantú syndrome. Nature Genetics, 2012, 44, 793-796.	9.4	184
484	Gender gap in acute coronary heart disease: Myth or reality?. World Journal of Cardiology, 2012, 4, 36.	0.5	52
485	Genetics and tailored therapy in cardiovascular disease. Netherlands Heart Journal, 2012, 20, 3-4.	0.3	1
486	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. American Journal of Human Genetics, 2012, 90, 410-425.	2.6	239

#	Article	IF	CITATIONS
487	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. American Journal of Human Genetics, 2012, 90, 753.	2.6	4
488	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2012, 90, 1116-1117.	2.6	0
489	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. PLoS ONE, 2012, 7, e50198.	1.1	40
490	Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. American Heart Journal, 2011, 161, 1171-1178.	1.2	41
491	Measuring and targeting aldosterone and renin in atherosclerosis—A review of clinical data. American Heart Journal, 2011, 162, 585-596.	1.2	24
492	Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ: British Medical Journal, 2011, 342, d1250-d1250.	2.4	120
493	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2011, 88, 6-18.	2.6	122
494	The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels. Cardiology Research and Practice, 2011, 2011, 1-8.	0.5	19
495	Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population. PLoS ONE, 2011, 6, e16639.	1.1	4
496	Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nature Genetics, 2010, 42, 1068-1076.	9.4	308
497	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens. Hypertension, 2010, 56, 533-539.	1.3	25
498	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With <i>CETP</i> Gene Polymorphisms. Circulation, 2010, 121, 52-62.	1.6	96
499	Bioinformatics challenges for genome-wide association studies. Bioinformatics, 2010, 26, 445-455.	1.8	477
500	Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems. PLoS ONE, 2010, 5, e12757.	1.1	11
501	Acute Intermittent Porphyria as a Cause of Respiratory Failure: Case Report. American Journal of Critical Care, 2009, 18, 180-178.	0.8	13
502	Shadows of complexity: what biological networks reveal about epistasis and pleiotropy. BioEssays, 2009, 31, 220-227.	1.2	162
503	Common Genetic Variation Near the Phospholamban Gene Is Associated with Cardiac Repolarisation: Meta-Analysis of Three Genome-Wide Association Studies. PLoS ONE, 2009, 4, e6138.	1.1	53
504	Search for a correlation between telomere length and severity of retinitis pigmentosa due to the dominant rhodopsin Pro23His mutation. Molecular Vision, 2009, 15, 592-7.	1.1	4

#	Article	IF	Citations
505	Male–female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Human Genetics, 2008, 124, 479-488.	1.8	21
506	N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Netherlands Heart Journal, 2008, 16, 73-78.	0.3	23
507	Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. American Journal of Cardiology, 2008, 102, 223-225.	0.7	5
508	Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. Atherosclerosis, 2008, 196, 349-355.	0.4	17
509	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 2008, 29, 2669-2680.	1.0	225
510	Association of renal function with cardiac calcifications in older adults: the cardiovascular health study. Nephrology Dialysis Transplantation, 2008, 24, 834-840.	0.4	55
511	Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation. Circulation Research, 2008, 102, 986-993.	2.0	112
512	Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1. Seminars in Thrombosis and Hemostasis, 2008, 34, 562-568.	1.5	13
513	Effects of lymphotoxin- $\hat{l}\pm$ gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease. Clinical Science, 2007, 112, 291-298.	1.8	28
514	Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. Current Opinion in Cardiology, 2007, 22, 267-272.	0.8	13
515	Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics, 2007, 89, 362-369.	1.3	30
516	Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 599-608.	0.7	527
517	Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men. American Journal of Clinical Nutrition, 2007, 86, 1524-1529.	2.2	37
518	Gene–gene interactions between <i>HNF4A</i> and <i>KCNJ11</i> in predicting TypeÂ2 diabetes in women. Diabetic Medicine, 2007, 24, 1187-1191.	1.2	27
519	Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. Journal of Thrombosis and Haemostasis, 2007, 5, 313-320.	1.9	44
520	Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2007, 100, 1548-1551.	0.7	18
521	The effects of polymorphisms in genes from the renin–angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context. Human Genetics, 2007, 122, 275-281.	1.8	16
522	Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics, 2006, 28, 432-444.	1.1	113

#	Article	IF	Citations
523	Thrombospondin-4 Ala387Pro polymorphism is not associated with vascular function and risk of coronary heart disease in US men and women. Thrombosis and Haemostasis, 2006, 95, 589-590.	1.8	7
524	A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study. BMC Medical Genetics, 2006, 7, 39.	2.1	39
525	Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 98, 751-753.	0.7	8
526	Letter Regarding Article by Arnlov et al, "Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals". Circulation, 2006, 113, e406-e407.	1.6	0
527	The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation, 2006, 21, 3106-3114.	0.4	93
528	The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thrombosis and Haemostasis, 2006, 96, 471-477.	1.8	33
529	Letter Regarding Article by Arnlov et al, "Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals― Circulation, 2006, 113, .	1.6	1
530	The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thrombosis and Haemostasis, 2006, 96, 471-7.	1.8	20
531	Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vascular Pharmacology, 2005, 42, 125-140.	1.0	37
532	Letters to the Editor. Hypertension, 2005, 46, e20.	1.3	1
533	Functional Characteristics of Coronary Vasomotor Function Following Intramyocardial Gene Therapy with Naked DNA Encoding for Vascular Endothelial Growth Factor165. Endothelium: Journal of Endothelial Cell Research, 2005, 12, 103-106.	1.7	5
534	Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria. Stroke, 2005, 36, 649-653.	1.0	44
535	Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. European Heart Journal, 2005, 26, 1314-1320.	1.0	51
536	C-reactive protein and microalbuminuria are associated with atrial fibrillation. International Journal of Cardiology, 2005, 98, 73-77.	0.8	80
537	Determination of vessel size: a putative framework to assess clinical outcome. International Journal of Cardiology, 2005, 103, 135-139.	0.8	4
538	Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. American Journal of Hypertension, 2005, 18, 342-347.	1.0	35
539	High Prevalence of Microalbuminuria in Chronic Heart Failure Patients. Journal of Cardiac Failure, 2005, 11, 602-606.	0.7	48
540	Anaemia predicts cardiovascular events in patients with stable coronary artery disease. Netherlands Heart Journal, 2005, 13, 254-258.	0.3	6

#	Article	IF	CITATIONS
541	Reduction of endothelial dysfunction following VEGF gene therapy. Netherlands Heart Journal, 2005, 13, 139-141.	0.3	2
542	Prognostic Value of Myeloperoxidase in Patients with Chest Pain. New England Journal of Medicine, 2004, 350, 516-518.	13.9	39
543	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. Circulation, 2004, 110, 2809-2816.	1.6	489
544	Sodium intake affects urinary albumin excretion especially in overweight subjects. Journal of Internal Medicine, 2004, 256, 324-330.	2.7	187
545	Framingham score and microalbuminuria: Combined future targets for primary prevention?. Kidney International, 2004, 66, S111-S114.	2.6	25
546	Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram. American Journal of Cardiology, 2004, 94, 1063-1067.	0.7	9
547	C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis, 2004, 172, 107-114.	0.4	48
548	Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?. International Journal of Cardiology, 2004, 93, 211-215.	0.8	58
549	Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. American Journal of Medicine, 2004, 116, 429-430.	0.6	78
550	Coronary vasomotor response is related to the angiographic extent of coronary sclerosis in patients with stable angina pectoris. Clinical Science, 2004, 106, 115-120.	1.8	8
551	Prognostic value of myeloperoxidase in patients with chest pain. New England Journal of Medicine, 2004, 350, 516-8; author reply 516-8.	13.9	9
552	Relation of electrocardiographic abnormalities to levels of serum C-reactive protein. American Journal of Cardiology, 2003, 91, 1358-1360.	0.7	5
553	Drug-induced renal function impairment: a population-based survey. Pharmacoepidemiology and Drug Safety, 2003, 12, 135-143.	0.9	5
554	Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia. Clinical Science, 2003, 104, 627-632.	1.8	37
555	1849 Left-ventricular hypertrophy increases the risk for microalbuminuria exclusively in hypertensive subjects. European Heart Journal, 2003, 24, 353.	1.0	0
556	P1752 C-reactive protein is related to impaired endothelium dependent relaxation and increased angiotensin II response. European Heart Journal, 2003, 24, 335.	1.0	0
557	Antineutrophil cytoplasmatic antibodies in patients with premature atherosclerosis: prevalence and association with risk factors. Journal of Internal Medicine, 2002, 251, 29-34.	2.7	6
558	A Data Mining-based Cross-Industry Process for Predicting Major Bleeding in Mechanical Circulatory Support. European Heart Journal Digital Health, 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
559	An agenda-setting paper on data sharing platforms: euCanSHare workshop. Open Research Europe, $0,1,80.$	2.0	1
560	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. Frontiers in Physiology, 0, 13, .	1.3	1
561	Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis. BMJ, The, 0, , e069881.	3.0	24